Galera Therapeutics Revenue and Competitors
Estimated Revenue & Valuation
- Galera Therapeutics's estimated annual revenue is currently $5.6M per year.
- Galera Therapeutics's estimated revenue per employee is $201,000
Employee Data
- Galera Therapeutics has 28 Employees.
- Galera Therapeutics grew their employee count by -32% last year.
Galera Therapeutics's People
| Name | Title | Email/Phone |
|---|---|---|
1 | Co-Founder, Executive Chair & Chief Operating Officer | Reveal Email/Phone |
2 | Chief Regulatory and Quality Officer | Reveal Email/Phone |
3 | CSO | Reveal Email/Phone |
4 | Chief Financial Officer | Reveal Email/Phone |
5 | SVP, Regulatory Affairs | Reveal Email/Phone |
6 | VP Commercial Operations | Reveal Email/Phone |
7 | VP Market Access | Reveal Email/Phone |
8 | SVP, Clinical Operations and Data Management | Reveal Email/Phone |
9 | Chief Scientific Officer | Reveal Email/Phone |
10 | Director Clinical Operations | Reveal Email/Phone |
Galera Therapeutics Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $43.2M | 192 | 8% | N/A | N/A |
#2 | $81.8M | 346 | 3% | N/A | N/A |
#3 | $11.7M | 58 | 0% | N/A | N/A |
#4 | $1011.8M | 5034 | -9% | N/A | N/A |
#5 | $44.8M | 178 | -3% | N/A | N/A |
#6 | $13.1M | 50 | -7% | N/A | N/A |
#7 | $16.5M | 82 | 41% | N/A | N/A |
#8 | $17.3M | 68 | -4% | N/A | N/A |
#9 | $67.9M | 402 | 30% | N/A | N/A |
#10 | $14.9M | 51 | -16% | N/A | N/A |
What Is Galera Therapeutics?
Galera Therapeutics is focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer.
keywords:N/A
N/A
Total Funding
28
Number of Employees
$5.6M
Revenue (est)
-32%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Galera Therapeutics News
2022-04-20 - Galera to Present at 2022 American Society of Clinical ...
MALVERN, PA Galera Therapeutics, Inc. (Nasdaq: GRTX) announced that clinical data from its Phase 3 ROMAN trial of avasopasem for severe...
2022-04-13 - Financial Survey: Galera Therapeutics (NASDAQ:GRTX ...
Financial Survey: Galera Therapeutics (NASDAQ:GRTX) versus Prestige Consumer Healthcare (NYSE:PBH). Posted by admin on Apr 22nd, 2022.
2022-04-06 - Galera Therapeutics, Inc. (NASDAQ:GRTX) Receives $12.45 ...
Galera Therapeutics, Inc. (NASDAQ:GRTX) Receives $12.45 Consensus PT from Analysts. Posted by admin on Apr 17th, 2022.
Other Companies in Malvern
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $7.4M | 28 | 33% | N/A |
#2 | $6.2M | 30 | -3% | N/A |
#3 | $8.5M | 30 | 11% | N/A |
#4 | $3.5M | 30 | -14% | N/A |
#5 | $5.5M | 31 | -3% | N/A |